PipelineRSSMay 13
FDA puts injection therapy COYA 302 on fast track for treating ALS
The FDA has given special fast-track status to COYA 302, an injection treatment being developed by Coya Therapeutics for ALS (a disease that weakens muscles over time). Early testing showed it might slow down how quickly the disease gets worse in a small group of patients. Fast-track status means the FDA will review this treatment more quickly than usual to help get it to patients faster.
WHY IT MATTERSALS patients now have a potential new treatment option moving through FDA review faster than standard timelines, which could mean access to COYA 302 years sooner if clinical trials continue to show benefit.